Abstract Number: L12 • ACR Convergence 2023
Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
Background/Purpose: TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis (PsO). TAK-279 is…Abstract Number: 0062 • ACR Convergence 2023
Differential Metabolic Profiles, Activation and Circadian Dynamics in Rheumatoid Arthritis and Psoriatic Arthritis Circulatory Monocytes
Background/Purpose: While Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) share many features, they are distinct in clinical presentation and molecular profile. As monocytes are crucial…Abstract Number: 0487 • ACR Convergence 2023
A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) can causes erositis including pericarditis and pleuritis. However, the rate of serositis in…Abstract Number: 0503 • ACR Convergence 2023
Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging
Background/Purpose: Right and Moll recognized the presence of spinal inflammation/axial disease in psoriatic arthritis (PsA) in their seminal work in 1973. The prevalence of axial…Abstract Number: 0778 • ACR Convergence 2023
The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial
Background/Purpose: Psoriatic Arthritis (PsA) is a painful disease of the joints and spine. Recent studies have described enteric dysbiosis as a possible pathological mechanism in…Abstract Number: 1388 • ACR Convergence 2023
Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI
Background/Purpose: Approximately 50% of PsA patients have persistent pain despite a well‐controlled inflammatory state, which has been attributed to non‐nociceptive pain and central sensitization. Enthesitis…Abstract Number: 1426 • ACR Convergence 2023
Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib
Background/Purpose: PsA is a heterogeneous disease, and identifying clinical phenotypes may assist clinical decision making. Patients (pts) treated with advanced therapies demonstrate varying treatment responses.…Abstract Number: 1640 • ACR Convergence 2023
Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network
Background/Purpose: Despite significant advances in psoriatic disease (PsD) therapeutics, treatment response remains suboptimal. Even in patients with psoriatic arthritis (PSA) that achieve seemingly controlled inflammation,…Abstract Number: 1787 • ACR Convergence 2023
Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease
Background/Purpose: In psoriatic arthritis (PsA) aberrant activation/migration of specific T cell subpopulations (Th17/Th9/MAIT cells) in the joint synovium induce synovial inflammation and pannus formation. Several…Abstract Number: 2232 • ACR Convergence 2023
Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
Background/Purpose: Monoclonal antibodies (mAbs) targeting the interleukin (IL)-23p19 subunit are effective in treating psoriatic disease; however, their molecular attributes may translate to differences in clinical…Abstract Number: 2248 • ACR Convergence 2023
Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice
Background/Purpose: In Psoriatic arthritis (PsA), patients who fail to respond to biologics and targeted synthetic therapies (ts/bDMARDs), switching to another ts/bDMARD should be considered. Failure…Abstract Number: PP09 • ACR Convergence 2023
Practicing Mindfulness to Improve Quality of Life
Background/Purpose: I’ve been living with symptoms of PSA and fibromyalgia for over 15 years. Four years ago, after flareup that severely impacted my mobility where…Abstract Number: 0161 • ACR Convergence 2023
Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Background/Purpose: National treatment recommendations are often used to optimize patient care and may differ from international recommendations. The aim of this study was to assess…Abstract Number: 0488 • ACR Convergence 2023
Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity
Background/Purpose: Patients with Psoriatic Arthritis (PsA) and Psoriasis (PsO) have an increased rate of work loss due to their disease compared the general population; however,…Abstract Number: 0504 • ACR Convergence 2023
Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory pathology that generates a substantial and progressive deterioration of functionality and quality of life. It is associated…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 81
- Next Page »